专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2006074192A2 TREATMENT OF INFLAMMATORY DISORDERS 审中-公开
标题翻译：治疗炎症性疾病
公开(公告)号：WO2006074192A2
公开(公告)日：2006-07-13
申请号：PCT/US2006000132
申请日：2006-01-03
申请人： BIONAUT PHARMACEUTICALS INC , AN WENQIAN FRANK , PARK JUN YOUNG , KHODADOUST MEHRAN , HESS HANS-JURGEN , HUSSOIN MD SAJJAT
发明人： AN WENQIAN FRANK , PARK JUN YOUNG , KHODADOUST MEHRAN , HESS HANS-JURGEN , HUSSOIN MD SAJJAT
CPC分类号： A61K31/203 , A61K31/05 , A61K31/09 , A61K31/165 , A61K31/19 , A61K31/343 , A61K31/365 , A61K31/366 , A61K31/37 , A61K31/415 , A61K31/428 , A61K31/498 , A61K31/517 , A61K31/56 , A61K31/57 , C07F9/12
摘要： Methods of treating an inflammatory disorder include administering an effective amount of a compound represented by Structural Formula (I). Ring A is optionally substituted, contains zero, one, two, or three double bonds, and is optionally fused to an aliphatic, aryl or heteroaryl ring; X is an optionally substituted 1 to 3 carbon aliphatic chain that is optionally fused to a monocyclic, optionally substituted, aliphatic, heterocyclic, aryl, or heteroaryl ring, wherein one or two carbons in X are optionally replaced with -O-, -S-, or -NR e -; Y is carbon or nitrogen; R 1 and R 2 are independently -H, -OH, -CN, -NO 2 , -NR f R g , halogen, optionally substituted alkyl, or optionally substituted alkoxy; or R 1 and R 2 together link the carbons to which they are bonded with a bond, -O-, -S-, or -NR h -; R 3 and R 4 are independently -H, -OH, -CN, -NO 2 , -NR i R j , halogen, optionally substituted alkyl, or optionally substituted alkoxy, or R 4 is =0; or R 3 and R 4 , taken together with the atoms to which they are bonded, form a monocyclic, optionally substituted, aliphatic, heterocyclic, aryl, or heteroaryl ring that is optionally fused to a monocyclic or bicyclic, optionally substituted, aliphatic, heterocyclic, aryl, or heteroaryl ring; R e -R j are independently -H or optionally substituted alkyl; and each of the OSM signaling inhibitor compounds has at least one hydrogen atom bonded to an oxygen, nitrogen, or sulfur atom. The OSM signaling inhibitor compounds also include pharmaceutically acceptable salt or solvates of the compounds represented by Structural Formula (I).
摘要翻译：治疗炎性病症的方法包括施用有效量的结构式（I）表示的化合物。环A任选被取代，含有0,1,2或3个双键，并且任选地与脂族，芳基或杂芳基环稠合; X是任选被1至3个碳的脂族链，其任选地与单环，任选取代的脂族，杂环，芳基或杂芳基环稠合，其中X中的一个或两个碳任选被-O-，-S- ，或-NR e - Y是碳或氮; R 1和R 2独立地是-H，-OH，-CN，-NO 2，-NR f，卤素，任选取代的烷基或任选取代的烷氧基; 或R 1和R 2 2一起连接与它们键合的碳键，-O-，-S-或-NR“ SUP> - ; R 3和R 4独立地是-H，-OH，-CN，-NO 2，-NR O，卤素，任选取代的烷基或任选取代的烷氧基，或R 4是= O; 或R 3和R 4与它们所键合的原子一起形成单环，任选取代的脂族，杂环，芳基或杂芳基环，其是任选地与单环或双环，任选取代的脂族，杂环，芳基或杂芳基环稠合; R e独立地是-H或任选取代的烷基; 并且每个OSM信号传导抑制剂化合物具有至少一个与氧，氮或硫原子键合的氢原子。 OSM信号传导抑制剂化合物还包括由结构式（I）表示的化合物的药学上可接受的盐或溶剂合物。

2. 发明申请

WO2007081835A3 MODULATORS OF HYPOXIA INDUCIBLE FACTOR-1 AND RELATED USES 审中-公开
标题翻译： HYPOXIA诱导因子-1的调节剂及相关用途
公开(公告)号：WO2007081835A3
公开(公告)日：2008-08-14
申请号：PCT/US2007000340
申请日：2007-01-09
申请人： BTG INT LTD , KHODADOUST MEHRAN , HESS HANS-JURGEN , HUSSON SAJJAT , BRUENING REIMAR C , GARDINER GREGORY E
发明人： KHODADOUST MEHRAN , HESS HANS-JURGEN , HUSSON SAJJAT , BRUENING REIMAR C , GARDINER GREGORY E
IPC分类号： C07J19/00 , A61K31/585 , A61P35/00 , C07J41/00 , C07J43/00
CPC分类号： C07J19/00 , C07J19/005 , C07J41/0005 , C07J41/0038 , C07J43/003
摘要： The invention features compounds of formulas I or II: and pharmaceutically acceptable salts and prodrugs thereof, as well methods for modulating the effects of local and systemic hypoxic events using the compounds.
摘要翻译：本发明具有式I或II化合物及其药学上可接受的盐和前药，以及使用该化合物调节局部和全身缺氧事件的作用的方法。

3. 发明申请

WO2006029018A2 COMBINATORIAL CHEMOTHERAPY TREATMENT USING NA+/K+-ATPASE INHIBITORS 审中-公开
标题翻译：使用NA + / K + -ATPASE抑制剂的组合治疗
公开(公告)号：WO2006029018A2
公开(公告)日：2006-03-16
申请号：PCT/US2005031418
申请日：2005-09-02
申请人： BIONAUT PHARMACEUTICALS INC , KHODADOUST MEHRAN , SHARMA AJAY
发明人： KHODADOUST MEHRAN , SHARMA AJAY
CPC分类号： A61K45/06 , A61K31/585 , A61K2300/00
摘要： The reagent, pharmaceutical formulation, kit, and methods of the invention provides a new approach to alleviate or eliminate certain negative effects associated with the use of certain cancer treatment agents (e.g. chemotherapy therapeutics, etc.) or regimens (e.g. radio therapies, etc.) including stimulation of the hypoxic stress response in tumor cells.
摘要翻译：本发明的试剂，药物制剂，试剂盒和方法提供了一种减轻或消除与使用某些癌症治疗剂（例如化疗治疗剂等）或方案（例如放射治疗等）相关的某些负面影响的新方法。）包括刺激肿瘤细胞中的缺氧应激反应。

4. 发明申请

WO2006044916A3 USE OF NA+/ K+-ATPASE INHIBITORS AND ANTAGONISTS THEREOF 审中-公开
标题翻译：使用NA + / K + -ATPASE抑制剂及其拮抗剂
公开(公告)号：WO2006044916A3
公开(公告)日：2007-01-04
申请号：PCT/US2005037486
申请日：2005-10-18
申请人： BIONAUT PHARMACEUTICALS INC , KHODADOUST MEHRAN , SHARMA AJAY
发明人： KHODADOUST MEHRAN , SHARMA AJAY
IPC分类号： A61K31/56
CPC分类号： A61K31/56 , A61K31/58 , A61K31/704 , A61K31/7048
摘要： The reagent, pharmaceutical formulation, kit, and methods of the invention provides a new approach for treating hypoxia-related pathological conditions, such as Alzheimer's Disease, and those involving excessive angiogenesis, especially those non-cancer pathological conditions. The invention provides the use of Na + /K + -ATPase inhibitors, such as cardiac glycosides (e.g. ouabain and proscillaridin, etc.), either alone or in combination with other standard therapeutic agents for treating such conditions. The invention also relates to the use of cardiac glycoside inhibitors / antagonists as reagents, pharmaceutical formulations, or in kits and methods for treating conditions arising from excessive amount of cardiac glycosides, including all symptoms of digitalis poisoning, depression, hypertension, etc. The pharmaceutical formulation of the invention may be delivered to a patient either systemically or locally, or both. The pharmaceutical formulations of the invention may be delivered either in one dose, or continuously over a sustained period of time using, for example, sustained drug delivery devices.
摘要翻译：本发明的试剂，药物制剂，试剂盒和方法提供了治疗缺氧相关病理状况（例如阿尔茨海默病）和涉及过度血管生成的那些的新方法，特别是那些非癌症病理状况。本发明提供单独使用或与其它组合使用的Na + + / K + + / - ATP酶抑制剂，例如强心苷（例如哇巴因和前列腺素等）用于治疗这些病症的标准治疗剂。本发明还涉及使用强心苷抑制剂/拮抗剂作为试剂，药物制剂，或用于治疗由过量的强心苷引起的病症的试剂盒和方法，包括洋地黄中毒，抑郁症，高血压等所有症状。药物本发明的制剂可以全身或局部地递送到患者，或两者。本发明的药物制剂可以使用例如持续的药物递送装置以一个剂量或持续的时间段连续递送。

5. 发明申请

WO2006029020A3 TREATMENTS OF REFRACTORY CANCERS USING NA+/K+-ATPASE INHIBITORS 审中-公开
标题翻译：使用NA + / K + -ATPASE抑制剂治疗癌症患者
公开(公告)号：WO2006029020A3
公开(公告)日：2006-06-01
申请号：PCT/US2005031421
申请日：2005-09-02
申请人： BIONAUT PHARMACEUTICALS INC , KHODADOUST MEHRAN , SHARMA AJAY
发明人： KHODADOUST MEHRAN , SHARMA AJAY
IPC分类号： A61K31/7048 , A61K31/17 , A61K31/365 , A61K31/395 , A61K31/407 , A61K31/4745 , A61K31/505 , A61K31/70 , A61K31/7068 , A61K33/24 , A61K39/395 , A61P35/00
CPC分类号： A61K31/395 , A61K31/17 , A61K31/365 , A61K31/407 , A61K31/4745 , A61K31/505 , A61K31/513 , A61K31/70 , A61K31/7048 , A61K31/7068 , A61K31/7072 , A61K33/24 , A61K39/39541 , A61K2300/00
摘要： The reagent, pharmaceutical formulation, kit, and methods of the invention provides a new approach to treat refractory cancers using Na + /K + -ATPase inhibitors, such as cardiac glycosides (e.g. ouabain or proscillaridin, etc.).
摘要翻译：本发明的试剂，药物制剂，试剂盒和方法提供了一种使用Na + / K + + ATPase抑制剂治疗难治性癌症的新方法，例如强心苷（例如哇巴因或前列腺素等）。

6. 发明申请

WO2007016656A3 MODULATORS OF HYPOXIA INDUCIBLE FACTOR-1 AND RELATED USES FOR THE TREATMENT OF OCULAR DISORDERS 审中-公开
标题翻译： HYPOXIA诱导因子-1的调节因子及治疗眼病的相关应用
公开(公告)号：WO2007016656A3
公开(公告)日：2007-06-07
申请号：PCT/US2006030224
申请日：2006-08-01
申请人： BIONAUT PHARMACEUTICALS , KHODADOUST MEHRAN
发明人： KHODADOUST MEHRAN
IPC分类号： A61K31/58 , A61K31/585 , C07J17/00 , C07J41/00
CPC分类号： A61K31/704 , A61K31/7048 , A61K39/395 , A61K2300/00
摘要： Methods for treatment of ocular disorders using steroids modulate the effects of local and systemic hypoxic events mediated by hypoxia inducible factor- 1 (HIF-1). Steroids that are useful as HIF-1 modulators include bufalin, digitoxigenin, digoxin, lanatoside C, strophantin K, uzarigenin, ouabain and proscillaridin. In some embodiments the ocular disorder is characterized by ischmia.
摘要翻译：使用类固醇治疗眼部疾病的方法调节由缺氧诱导因子-1（HIF-1）介导的局部和全身缺氧事件的影响。可用作HIF-1调节剂的类固醇包括蟾蜍灵，洋地黄毒苷，地高辛，藜芦苷C，维生素K，紫苏碱，哇巴因和前列腺素。在一些实施方案中，眼部疾病的特征在于异位症。

7. 发明申请

WO2007016656A8 MODULATORS OF HYPOXIA INDUCIBLE FACTOR-1 AND RELATED USES FOR THE TREATMENT OF OCULAR DISORDERS 审中-公开
标题翻译：缺氧诱导因子-1调节剂及相关治疗眼科疾病
公开(公告)号：WO2007016656A8
公开(公告)日：2007-07-19
申请号：PCT/US2006030224
申请日：2006-08-01
申请人： BIONAUT PHARMACEUTICALS , KHODADOUST MEHRAN
发明人： KHODADOUST MEHRAN
IPC分类号： A61K31/58 , A61K31/585 , C07J17/00 , C07J41/00
CPC分类号： A61K31/704 , A61K31/7048 , A61K39/395 , A61K2300/00
摘要： Methods for treatment of ocular disorders using steroids modulate the effects of local and systemic hypoxic events mediated by hypoxia inducible factor- 1 (HIF-1). Steroids that are useful as HIF-1 modulators include bufalin, digitoxigenin, digoxin, lanatoside C, strophantin K, uzarigenin, ouabain and proscillaridin. In some embodiments the ocular disorder is characterized by ischmia.
摘要翻译：使用类固醇治疗眼部疾病的方法调节由缺氧诱导因子-1（HIF-1）介导的局部和全身性缺氧事件的影响。可用作HIF-1调节剂的类固醇包括蟾毒灵，洋地黄毒苷，地高辛，毛花甙甙C，strophantin K，z鱼精蛋白，哇巴因和原鲨酰胺。在一些实施方案中，眼部病症的特征在于缺血。

8. 发明申请

WO2005060951A3 ANTI-NEOPLASTIC AGENTS, COMBINATION THERAPIES AND RELATED METHODS 审中-公开
标题翻译：抗神经药物，组合疗法及相关方法
公开(公告)号：WO2005060951A3
公开(公告)日：2005-11-24
申请号：PCT/US2004042589
申请日：2004-12-20
申请人： BIONAUT PHARMACEUTICALS , KHODADOUST MEHRAN
发明人： KHODADOUST MEHRAN
IPC分类号： A61K31/122 , A61K31/155 , A61K31/167 , A61K31/216 , A61K31/4709 , A61K31/498 , A61K31/704 , A61K45/06 , G01N33/50 , A61P35/00 , C12N5/22 , G01N33/15
CPC分类号： G01N33/5011 , A61K31/122 , A61K31/155 , A61K31/167 , A61K31/216 , A61K31/4709 , A61K31/498 , A61K31/704 , A61K31/7048 , A61K45/06 , G01N2500/10 , A61K2300/00
摘要： In certain aspects, the invention relates to the discovery of novel compositions for use in the treatment of a neoplastic disorder. Active agents are e.g. ouabain, niclosamide, casodex. Further aspects of the invention relate to the discovery that cell signaling may be exploited to identify significant genes in cancer cell lines and to generate reporter gene systems that may be used, for example, to identify anti-neoplastic agents and effective combinations thereof.
摘要翻译：在某些方面，本发明涉及用于治疗肿瘤性疾病的新型组合物的发现。活性剂是例如哇巴因，氯硝柳胺，casodex。本发明的其它方面涉及可以利用细胞信号传导来鉴定癌细胞系中的重要基因并产生可用于鉴定抗肿瘤剂及其有效组合的报告基因系统的发现。

9. 发明专利

AT509630T 未知
公开(公告)号：AT509630T
公开(公告)日：2011-06-15
申请号：AT05794315
申请日：2005-09-02
申请人： BIONAUT PHARMACEUTICALS INC
发明人： KHODADOUST MEHRAN , SHARMA AJAY
IPC分类号： A61K31/704 , A61P35/00
摘要： The reagent, pharmaceutical formulation, kit, and methods of the invention provides a new approach for treating pancreatic cancers. The invention provides the use of Na + /K + -ATPase inhibitors, such as cardiac glycosides (e.g. ouabain and proscillaridin, etc.), either alone or in combination with other standard therapeutic agents (chemo- or radio-therapies, etc.) for treating pancreatic cancers.

10. 发明公开

EP1928470A4 MODULATORS OF HYPOXIA INDUCIBLE FACTOR-1 AND RELATED USES FOR THE TREATMENT OF OCULAR DISORDERS 审中-公开
标题翻译：缺氧诱导因子1与相关应用眼部疾病治疗的调节剂
公开(公告)号：EP1928470A4
公开(公告)日：2010-09-15
申请号：EP06789280
申请日：2006-08-01
申请人： BIONAUT PHARMACEUTICALS INC
发明人： KHODADOUST MEHRAN , SHARMA AJAY
IPC分类号： A61K31/58 , A61K31/585 , A61P27/00 , A61P27/06 , A61P27/12 , C07J17/00 , C07J41/00
CPC分类号： A61K31/704 , A61K31/7048 , A61K39/395 , A61K2300/00

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式